P.I. Lundmo

928 total citations
22 papers, 755 citations indexed

About

P.I. Lundmo is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, P.I. Lundmo has authored 22 papers receiving a total of 755 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Endocrinology, Diabetes and Metabolism, 6 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in P.I. Lundmo's work include Hormonal and reproductive studies (9 papers), Prostate Cancer Diagnosis and Treatment (5 papers) and Prostate Cancer Treatment and Research (5 papers). P.I. Lundmo is often cited by papers focused on Hormonal and reproductive studies (9 papers), Prostate Cancer Diagnosis and Treatment (5 papers) and Prostate Cancer Treatment and Research (5 papers). P.I. Lundmo collaborates with scholars based in Norway, Sweden and United States. P.I. Lundmo's co-authors include John T. Isaacs, Donald L. Gill, Alison D. Short, Yuzo Furuya, Natasha Kyprianou, Paula Martikainen, Hugh F. English, R. Berges, A. Sunde and Kjell J. Tveter and has published in prestigious journals such as The Journal of Urology, International Journal of Radiation Oncology*Biology*Physics and Journal of Chromatography A.

In The Last Decade

P.I. Lundmo

22 papers receiving 717 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P.I. Lundmo Norway 11 332 300 170 94 86 22 755
W. HEYNS Belgium 9 194 0.6× 373 1.2× 126 0.7× 320 3.4× 47 0.5× 12 665
M-H. Tan Singapore 3 317 1.0× 338 1.1× 132 0.8× 113 1.2× 137 1.6× 6 703
Carlo M. Veneziale United States 18 104 0.3× 496 1.7× 218 1.3× 117 1.2× 32 0.4× 47 870
Y. Nishino Germany 18 97 0.3× 229 0.8× 201 1.2× 64 0.7× 163 1.9× 53 798
Gerasimos P. Vandoros Greece 14 111 0.3× 353 1.2× 40 0.2× 154 1.6× 195 2.3× 24 797
Ricardo Marques Portugal 13 81 0.2× 271 0.9× 86 0.5× 154 1.6× 82 1.0× 20 492
Prachi Bajpai United States 15 71 0.2× 507 1.7× 28 0.2× 159 1.7× 98 1.1× 34 754
Sylvie Fauconnet France 16 96 0.3× 510 1.7× 44 0.3× 249 2.6× 136 1.6× 27 749
Marjo Malinen Finland 19 171 0.5× 555 1.9× 55 0.3× 158 1.7× 178 2.1× 35 935
Ting-Ting Chao Taiwan 12 152 0.5× 539 1.8× 32 0.2× 93 1.0× 207 2.4× 21 779

Countries citing papers authored by P.I. Lundmo

Since Specialization
Citations

This map shows the geographic impact of P.I. Lundmo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P.I. Lundmo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P.I. Lundmo more than expected).

Fields of papers citing papers by P.I. Lundmo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P.I. Lundmo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P.I. Lundmo. The network helps show where P.I. Lundmo may publish in the future.

Co-authorship network of co-authors of P.I. Lundmo

This figure shows the co-authorship network connecting the top 25 collaborators of P.I. Lundmo. A scholar is included among the top collaborators of P.I. Lundmo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P.I. Lundmo. P.I. Lundmo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Iversen, Peter, Jan‐Erik Johansson, Pär Lodding, et al.. (2006). Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer Updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years. Scandinavian Journal of Urology and Nephrology. 40(6). 441–452. 28 indexed citations
2.
3.
4.
Widmark, Anders, Sophie D. Fosså, P.I. Lundmo, et al.. (2003). Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology. 61(1). 145–151. 68 indexed citations
5.
Widmark, Anders, et al.. (1999). Does prophylactic radiotherapy prevent antiandrogen induced gynecomastia? Evaluation of patients in the randomized Scandinavian trial SPCG7/SFUO-3. 262–263. 1 indexed citations
6.
Widmark, Anders, et al.. (1999). 1010 Does prophylactic radiotherapy prevent antiandrogen induced gynecomastia? Evaluation of patients in the randomized scandinavian trial SPCG7/SFUO-3. International Journal of Radiation Oncology*Biology*Physics. 45(3). 262–263. 11 indexed citations
7.
Lundmo, P.I.. (1998). Rapid analysis of C19-steroid metabolism by high-performance liquid chromatography and in-line monitoring of radioactivity. Journal of Chromatography A. 308. 289–294. 2 indexed citations
8.
Furuya, Yuzo, P.I. Lundmo, Alison D. Short, Donald L. Gill, & John T. Isaacs. (1994). The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin.. PubMed. 54(23). 6167–75. 272 indexed citations
9.
Samdal, Frode, et al.. (1993). Sexual Function after Transurethral Prostatectomy. Scandinavian Journal of Urology and Nephrology. 27(1). 27–29. 13 indexed citations
10.
Isaacs, John T., P.I. Lundmo, R. Berges, et al.. (1992). Androgen Regulation of Programmed Death of Normal and Malignant Prostatic Cells. Journal of Andrology. 13(6). 457–464. 136 indexed citations
11.
Beisland, Hans Olav, Bruce Binkowitz, Peter Ekman, et al.. (1992). Scandinavian Clinical Study of Finasteride in the Treatment of Benign Prostatic Hyperplasia. European Urology. 22(4). 271–277. 37 indexed citations
12.
Hole, A., et al.. (1992). Digital Rectal Examination Does Not Increase Serum Concentrations of Prostatic-Specific Antigen. Clinical Chemistry. 38(5). 782–782. 4 indexed citations
13.
Samdal, Frode, et al.. (1991). Orchidectomy or LHRH-Analogue? Which Do the Patients Prefer and What Treatment Would Norwegian Urologists Prefer if They Had Advanced Cancer of the Prostate?. Scandinavian Journal of Urology and Nephrology. 25(3). 197–199. 18 indexed citations
14.
Halgunset, Jostein, A. Sunde, & P.I. Lundmo. (1987). Retinoic acid (RA): An inhibitor of 5α-reductase in human prostatic cancer cells. Journal of Steroid Biochemistry. 28(6). 731–736. 21 indexed citations
15.
Lundmo, P.I., A. Sunde, & Kjell J. Tveter. (1985). Age dependent changes in androgen metabolism in the rat prostate. Journal of Steroid Biochemistry. 22(4). 521–528. 10 indexed citations
16.
Lundmo, P.I., A. Sunde, & Kjell J. Tveter. (1985). Metabolism of androgens in the seminal vesicles and the different lobes of the prostate in young mature rats. Journal of Steroid Biochemistry. 22(4). 513–519. 23 indexed citations
17.
Lundmo, P.I., A. Sunde, & Kjell J. Tveter. (1985). A new dihydrotestosterone-forming index (DHTi). Journal of Steroid Biochemistry. 22(4). 529–532. 3 indexed citations
18.
Sunde, A., et al.. (1985). [The first babies in Norway after in vitro fertilization].. PubMed. 105(8). 565–7. 1 indexed citations
19.
Sunde, Arne, P.I. Lundmo, G. Kopstad, Kåre E. Tvedt, & Olav A. Haugen. (1983). 131 A spontaneous adenocarcinoma of the rat coagulating gland. Journal of Steroid Biochemistry. 19. 44–44. 8 indexed citations
20.
Sunde, Arne & P.I. Lundmo. (1982). Separation of 5α-reduced androgens by reversed-phase high-performance liquid chromatography. Journal of Chromatography A. 242(2). 381–384. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by W. HEYNS Breakdown of academic impact, for papers by M-H. Tan Breakdown of academic impact, for papers by Carlo M. Veneziale Breakdown of academic impact, for papers by Y. Nishino Breakdown of academic impact, for papers by Gerasimos P. Vandoros Breakdown of academic impact, for papers by Ricardo Marques Breakdown of academic impact, for papers by Prachi Bajpai Breakdown of academic impact, for papers by Sylvie Fauconnet Breakdown of academic impact, for papers by Marjo Malinen Breakdown of academic impact, for papers by Ting-Ting Chao
Rankless by CCL
2026